about
Valproic acid-induced thrombocytopenia may cause wound nonhealing in individuals with schizophrenia.Myoclonus as an indicator of infection in patients with schizophrenia treated with clozapine.Incongruent reduction of serotonin transporter associated with suicide attempts in patients with major depressive disorder: a positron emission tomography study with 4-[18F]-ADAMReduced Dopamine Transporter Availability and Neurocognitive Deficits in Male Patients with Alcohol Dependence.Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM.Increased risk of cognitive impairment in patients with components of metabolic syndrome.In-hospital mortality among electroconvulsive therapy recipients: A 17-year nationwide population-based retrospective study.Rapid Management of Trigeminal Neuralgia and Comorbid Major Depressive Disorder With Duloxetine.Seasonality of hospital admissions and birth dates among inpatients with eating disorders: a nationwide population-based retrospective study.Allopurinol for treatment-resistant schizophrenia and epilepsy: a case report.Paraphilias in schizophrenia: differential diagnosis and treatment with selective serotonin reuptake inhibitors.Incongruent changes in heart rate variability and body weight after discontinuing aerobic exercise in patients with schizophrenia.Superior anti-suicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression.Continuing weight-loss effect after topiramate discontinuation in obese persons with schizophrenia: a pilot open-label study.Associations Between Depression/Anxiety and Headache Frequency in Migraineurs: A Cross-Sectional Study.Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls.Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence.Harm avoidance involved in mediating the association between nerve growth factor (NGF) gene polymorphisms and antidepressant efficacy in patients with major depressive disorder.A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.Tryptophan depletion in addictive behaviours.SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.Reactive heart rate variability in male patients with first-episode major depressive disorder.Acute renal failure after paliperidone overdose: a case report.DRD3 variation associates with early-onset heroin dependence, but not specific personality traits.DRD2 and ANKK1 genes associate with late-onset heroin dependence in men.Limitations of measuring blood cytokines in biological psychiatry.A Pilot Study of Randomized, Head-to-Head of Metformin Versus Topiramate in Obese People With Schizophrenia.Secondary mania associated with enterococcal meningitis in an elderly patient.Novelty seeking mediates the effect of DRD3 variation on onset age of amphetamine dependence in Han Chinese population.Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment.Zotepine-associated vitamin B12 deficiency and pancytopenia.Global-cognitive health metrics: A novel approach for assessing cognition impairment in adult population.Differential effect of the DRD3 genotype on inflammatory cytokine responses during abstinence in amphetamine-dependent womenClozapine-Associated Cytomegalovirus Colitis and Related Critical Illness in a Patient With Neither Neutropenia Nor AgranulocytosisAdjunctive Donepezil for Anxiety Symptoms With Poor Response to Paroxetine in a Patient With Probable Mild Cognitive ImpairmentBenzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight IndividualsRapid development of severe hypertriglyceridemia and hypercholesterolemia during augmentation of quetiapine with valproic acidPaliperidone-associated seizure after discontinuation of sodium valproate: a case reportMultiple intracerebral hemorrhages in an elderly patient after adding quetiapine to a stable warfarin regimen
P50
Q33416390-DCFFCB00-01BB-4C11-AD98-F14EEE07B9DBQ34419663-255997CF-48E5-498D-ACB1-F4F9D99E3751Q35179035-56BC70D0-AF86-4B3B-A696-A5AC5DEC6CC1Q35676952-4BBE4ADF-E9AB-4120-85E4-FD8C02587DACQ35965853-DCE86A91-C017-4F84-8BF4-9E3689A2226AQ37257005-B33D2D06-CACB-444E-A46C-EBEF9F0AD7B9Q38960130-0DA35936-DB25-437C-B683-0B32FC6FC2DCQ39207602-6531AE4A-BB92-435A-8A01-1921A1051775Q39287449-A64C5249-BA0E-4EB1-9479-19DABAA6DEF0Q43058921-C234E88A-724E-4698-96A3-ACABC9FBE555Q43093476-F0B3DF6E-BD73-4186-9F16-ECFD65D92FDFQ47277732-1EBD084F-AD88-4806-A1CB-72F5D4ED1434Q47332189-E7BA4609-9258-4089-8229-137151A5047AQ47580421-E0E440ED-428E-4DE9-B1CE-82E654024E03Q47672483-F977A828-DE54-4E66-8E70-96455FD6EC13Q47732794-29E53F13-685F-4582-A0EB-638EC09B1154Q48010755-A9341E3E-BB9C-4A6A-9973-68FE8C4A6713Q48015445-4B427EB1-0F86-42CC-86C5-399356DCD147Q48081935-ECFBC244-7701-41C9-A5C0-8262366FB19AQ48122925-C44E0F99-AEFD-48C6-8003-62C60F381CCEQ48150101-5304DE41-000B-4ED6-8E72-D37A3A7CBFE1Q48151591-C8A80EC2-2820-4934-8E71-048BD6648FDDQ48227754-7EEF0860-8B62-4E1C-8650-AABECC6F292BQ48766504-33F707AF-7631-44CF-99DC-E6B33F89848EQ48899032-7EA9E379-36BF-40F0-9956-C4F17004D537Q50270226-00BF287C-ABB9-46B6-BA4B-D97EF9180EC7Q51116635-307FD4D3-FF2A-4B23-B48D-B736817A4074Q51373080-A8214789-158B-497C-9A62-F59034E8501FQ51460566-17182959-5FD8-41DC-92C2-D5AC77444FB9Q52311463-FE5B206A-C926-4C5B-8A60-C88115788094Q53644333-8F32F422-6D57-485F-A455-F96E0E2E4E08Q53743649-523B9BF0-8922-4E7C-9C36-32B24F45E880Q54943969-15CD9D6C-DDC8-470F-8FF8-B69DE5A6D80BQ56761594-5020D76C-58C4-46CF-B066-5F9735925B48Q57033408-04302EBE-E131-45A9-8222-09BBD389E2AEQ57066155-DFFC8D98-056A-45A0-A0C0-087E2F3E28A7Q58729510-284C69A2-41CB-48C4-9F0C-E06EEEA6A8D0Q83507351-E46511AF-A618-46C7-868B-EC6CAEA326D7Q83507357-AEA5555A-EBF9-49CC-B588-B29CA67045DAQ84162357-332762D0-C4F9-42EA-BB43-DE4A3D7C7FF8
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1138-5586
@en
name
Chih-Sung Liang
@ast
Chih-Sung Liang
@en
Chih-Sung Liang
@es
Chih-Sung Liang
@nl
type
label
Chih-Sung Liang
@ast
Chih-Sung Liang
@en
Chih-Sung Liang
@es
Chih-Sung Liang
@nl
prefLabel
Chih-Sung Liang
@ast
Chih-Sung Liang
@en
Chih-Sung Liang
@es
Chih-Sung Liang
@nl
P106
P1153
57204603196
P31
P496
0000-0003-1138-5586